Population Pharmacokinetic Modeling Combined With Machine Learning Approach Improved Tacrolimus Trough Concentration Prediction in Chinese Adult Liver Transplant Recipients
Authors:
- 29 December 2022
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (3) , 314-325
Abstract
This study aimed to develop and evaluate a population pharmacokinetic (PPK) combined machine learning approach to predict tacrolimus trough concentrations for Chinese adult liver transplant recipients in the early posttransplant period. Tacrolimus trough concentrations were retrospectively collected from routine monitoring records of liver transplant recipients and divided into the training data set (1287 concentrations in 145 recipients) and the test data set (296 concentrations in 36 recipients). A PPK model was first established using NONMEM. Then a machine learning model of Xgboost was adapted to fit the estimated individual pharmacokinetic parameters obtained from the PPK model with Bayesian forecasting. The performance of the final PPK model and Xgboost model was compared in the test data set. In the final PPK model, tacrolimus daily dose, postoperative days, hematocrit, aspartate aminotransferase, and concomitant voriconazole, were identified to significantly influence the clearance. The postoperative days along with hematocrit significantly influence the volume of distribution. In the Xgboost model, the first 5 predictors for predicting the clearance were concomitant with voriconazole, sex, single nucleotide polymorphisms of CYP3A4*1G and CYP3A5*3 in recipients, and tacrolimus daily dose, for the volume of distribution were postoperative days, age, weight, total bilirubin and graft : recipient weight ratio. In the test data set, the Xgboost model showed the minimum median prediction error of tacrolimus concentrations, less than the PPK model with or without Bayesian forecasting. In conclusion, a PPK combined machine learning approach could improve the prediction of tacrolimus concentrations for Chinese adult liver transplant recipients in the early posttransplant period.Keywords
This publication has 35 references indexed in Scilit:
- Tacrolimus dose individualization in “de novo” patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiologyInt. Journal of Clinical Pharmacology and Therapeutics, 2013
- The Impact of Sulfonylureas on Tacrolimus Apparent Clearance Revealed by a Population Pharmacokinetics Analysis in Chinese Adult Liver-Transplant PatientsTherapeutic Drug Monitoring, 2012
- Sex-Dependent Differences in Cytochrome P450 3A Activity as Assessed by Midazolam Disposition in Humans: A Meta-AnalysisDrug Metabolism and Disposition, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IClinical Pharmacokinetics, 2010
- Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patientsJournal of Clinical Pharmacy and Therapeutics, 2007
- Randomized Controlled Trial of Tacrolimus Versus Microemulsified Cyclosporin (TMC) in Liver Transplantation: Poststudy Surveillance to 3 YearsAmerican Journal of Transplantation, 2006
- Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation:A Meta-AnalysisAmerican Journal of Transplantation, 2006
- Population Pharmacokinetics of Tacrolimus in Whole Blood and Plasma in Asian Liver Transplant PatientsClinical Pharmacokinetics, 2006
- Sex Is A Major Determinant of Cyp3a4 Expression in Human LiverHepatology, 2003
- Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantationLiver Transplantation, 2003